Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)

Immunostimulating Interstitial Laser Thermotherapy in Patients With Locally Advanced Pancreatic Cancer: Results of a Prospective, Open, Non Comparative Study

10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy). Safety and feasibility of imILT on LAPC will be evaluated as primary objective. Secondary objectives will be QoL after imILT, study of the immune reaction after imILT, oncological analysis of patients suffering from LAPC submitted to imILT.

Inclusion Criteria:

• Diagnosis of stage III locally advanced pancreatic cancer
• No further neoadjuvant treatments are doable
• Eastern Cooperative Oncology Group performance status < 1

Exclusion Criteria:

• No other concomitant oncological treatments (hormonal, immunotherapies, etc)
• Suffering from other neoplasms
• Suffering from HIV
• Suffering from autoimmune diseases
• Concomitant medication with steroids